A dirty little secret
=====================

*Mycobacterium tuberculosis* is a devastating pathogen that kills \>1.5 million people each year, but controlled use of its cell wall activates macrophages in ways that can be harnessed for therapy. For example, *M. bovis* Bacille Calmette-Guérin (BCG) is one of the most widely used antitumor adjuvant therapies in humans. Injection of BCG into the bladder mediates regression of transitional cell carcinomas by stimulating a vigorous local immune response, bathing tumors in cytokines and activated immune cells ([@bib7]). Similarly, Freund's adjuvant, an emulsion of mycobacterial cell wall components in paraffin oil, is mixed with antigens to optimize memory T and B cell responses in mice ([@bib10]). In 1989, Charles Janeway Jr. dubbed the widespread use of Freund's adjuvant "the immunologist's dirty little secret" ([@bib14]). This practice was considered a secret because the co-stimulatory properties of adjuvants were overshadowed by the focus on antigen interactions with T and B cell receptors. 20 yr later, the role of innate receptors in licensing adaptive responses is no longer a secret, but Freund's adjuvant remains dirty. Freund's and BCG adjuvants contain hundreds of natural molecules, yet the particular components that mediate therapeutic effects have not been identified.

Janeway advocated systematically sorting through the components of empirically discovered adjuvants to identify the individual stimulatory molecules and their cellular receptors, especially those that lead to interleukin-1 (IL-1) secretion ([@bib14]). For Gram-negative bacteria, lipopolysaccharide (LPS) is the most potent cell wall component that leads to innate immune activation and sepsis ([Fig. 1](#fig1){ref-type="fig"}). Discovery of the mechanism by which LPS activates CD14, Toll-like receptor 4 (TLR4), and myeloid differentiation factor 88 (MyD88) represents a major advance in understanding Gram-negative bacterial sepsis, a cytokine-mediated disease. On page 2879 of this issue, [@bib13] identify a ligand-receptor interaction that plays a role in the characteristic immune process of mycobacterial infection: granuloma formation. Until recently, Mincle was an orphan receptor for which ligands were unknown. Now, this lectin is shown to bind and mediate responses to an immunodominant glycolipid in the mycobacterial cell wall, TDM ([Fig. 1](#fig1){ref-type="fig"}). Here, we discuss Mincle as a target for rational adjuvant design and review TLRs and C-type lectins as two major innate pathways for host response during *M. tuberculosis* infection.

![**Actinobacteria contain a unique outer layer composed of mycolate lipids.** One of those lipids, TDM, is an immunostimulant whose potency compares to Gram-negative bacterial LPS, but the nature of the inflammation triggered by these two molecules differ.](JEM_20092533R_RGB_Fig1){#fig1}

Cord factor controls inflammation, not cording
==============================================

In search of a bacterial factor that mediates a characteristic growth pattern known as cording, Hubert Bloch isolated a glycolipid from the tubercle bacillus ([@bib5]), the structure of which was solved as TDM ([Fig. 1](#fig1){ref-type="fig"}; [@bib18]). Although widely known as cord factor, this glycolipid is no longer believed to be the cause of bacterial cording. Instead, TDM has remained the focus of sustained research for five decades because of its ability to potently activate the innate immune system of mammals ([@bib12]). *M. tuberculosis* is encased in an outer membrane formed of very long chain α-branched, β-hydroxy fatty acids ([Fig. 1](#fig1){ref-type="fig"}). These unusual lipids are known as mycolic acids because the lipid type is found only in mycobacteria and related actinobacteria. Mycolate lipids like TDM are foreign molecules and can be considered *Actinomycetales*-specific biomarkers. Therefore, identifying the cellular receptors for TDM might begin to explain why mycobacteria, in contrast to many other types of bacteria, generate prominent granulomas during natural infection.

TDM strongly contributes to inflammation seen in mycobacterial infection. For example, injection of pure TDM in mice stimulates the formation of lung granulomas ([@bib3]) and induces a generalized wasting that mimics certain features of consumption in tuberculosis patients ([@bib16]; [@bib19]). Although mycobacteria contain several classes of immunostimulants, TDM has been demonstrated to be the most potent stimulator of IL-1, TNF, and granuloma formation among the BCG cell wall glycolipids ([@bib11]). After early studies showed that natural TDMs enhanced antibody production by B cells ([@bib4]), synthetic TDMs with simplified structures are being developed as therapeutic adjuvants ([@bib9]). These studies provide a strong rationale to understand which receptors on macrophages and dendritic cells mediate the response.

Vetting candidate receptors
===========================

The most extensively studied innate receptors for mycobacteria are TLRs and C-type lectins. Both cell surface receptor families lack intracellular signaling motifs and depend on adaptor proteins for signaling. TLRs signal through the adaptor MyD88. C-type lectins signal through adaptors DAP10, DAP12, or Fc receptor γ chain (FcRγ), all of which bind phosphorylated Syk proteins with immunoreceptor tyrosine activation motifs (ITAMs; [Fig. 2](#fig2){ref-type="fig"}). Before the studies of Mincle reported here, it was suspected that either TLRs ([@bib6]) or C-type lectins ([@bib22]) might be responsible for TDM-induced activation of macrophages. Either receptor family represents a plausible candidate based on their general patterns of ligand specificity. The TLR2-1 heterodimer is a lipid binding receptor that uses two hydrophobic pockets to sequester the hydrophobic triacylation units on the N terminus of bacterial proteins ([@bib15]). The finding that TLR2, in combination with other receptors, influences macrophage activation by TDM raised the possibility that TLR2 might in some way capture the mycolate lipid units ([@bib6]). In contrast, C-type lectins are carbohydrate-binding proteins and would be predicted to bind TDM's trehalose disaccharide ([Fig. 2](#fig2){ref-type="fig"}).

![**The mycobacterial lipid TDM and its synthetic analogue TDB exist as symmetric trehalose glycolipid structures.** Their receptor, Mincle, couples with Syk and the FcRγ chain.](JEM_20092533R_RGB_Fig2){#fig2}

The case for C-type lectins as TDM receptors was supported by a study earlier this year showing that TDM signaling involves Syk and FcRγ ([@bib22]). Deletion of Syk or any of its downstream signaling proteins (Card9, Bcl10, or Malt1) essentially eliminated measurable responses to TDM by mouse macrophages. Additionally, testing of Syk-associated proteins showed that the FcRγ, but not DAP12, was necessary for recognition of TDM ([Fig. 2](#fig2){ref-type="fig"}). Looking further upstream for cell surface receptors, it was determined that one of the FcRγ-associated proteins, Dectin-1, was not the putative receptor. The authors predicted that the TDM responses would involve another FcRγ-associated receptor such as Dectin-2, dendritic cell activating receptor, or Mincle ([@bib22]).

Sorting through cell walls
==========================

With this information, it might have been possible to discover a receptor for TDM by analyzing molecules in the Syk--FcRγ pathway, but the work reported here instead pursued the identification of Mincle ligands using reporter constructs. After demonstrating that Mincle binds to FcRγ in its transmembrane segment ([@bib23]), Mincle and FcRγ were transfected together with an ITAM-dependent expression system into lymphoid cells to generate a reporter line. Whereas early studies of Mincle suggested that it is activated by *Candida albicans* ([@bib8]; [@bib21]) or fungal saprophytes of the *Malassezia* genus ([@bib24]), [@bib13] linked Mincle to *M. tuberculosis*, a pathogen of worldwide importance. Following up on this important observation, the authors used the reporter to identify the particular cell wall structures that activate Mincle.

First, a targeted approach was used based on the annotation of Mincle's carbohydrate recognition domain (CRD; [@bib2]) as a mannose-binding motif ([Fig. 2](#fig2){ref-type="fig"}). To examine the contribution of mannose residues for Mincle activation, lipids from mycobacteria lacking mannosyl transferases and mannolipids were tested one by one for Mincle activity. The targeted experiments, however, yielded no results. Next, the authors undertook a systematic approach whereby all chromatographically separated cell wall components were exposed to the reporter line without regard to whether their structures contained mannose. This approach led to successful identification of TDM as the Mincle ligand. Thus, mycobacterial recognition by Mincle does not depend upon mannose-containing glycolipids. Although the final answer awaits further quantitative structure--function studies, the mannose-binding motif in Mincle likely contacts some aspect of the glucose disaccharide, trehalose, in TDM ([Fig. 2](#fig2){ref-type="fig"}). The apparent contradiction is resolved by understanding that proteins with mannose motifs also bind structurally related sugars like glucose.

This unbiased discovery approach is less dependent on assumptions, yet it is simple and effective. Although transcriptional profiling has transformed our ability to investigate responses to defined stimuli, it requires physically arraying libraries on chips and detection of individual transcripts. In contrast, all microbe-derived small molecules can be rapidly extracted and the eluent loaded onto a matrix to provide a stream of compounds that are individually fed into a biological testing system. This global analysis of bacterial extracts provides information about the number, relative potency, and structural relatedness of all bioactive compounds in an organism ([@bib17]; [@bib11]).

Is Mincle the major pathway?
============================

In mice, Mincle deletion essentially abolishes many aspects of the in vivo response to purified TDM, including granulomatous lung inflammation ([@bib13]). Thus, Mincle plays an essential role in response to TDM. However, mycobacteria produce several classes of immunostimulants, and only further investigation will determine whether blocking Mincle--TDM interactions also alters the course of mycobacterial infection. *M. tuberculosis* produces several compounds that act in parallel via TLR2, TLR9, mannose receptor, Dectin-1, NOD2, and other receptors. Illustrating the redundant nature of innate response to this pathogen, wild-type and TLR-deficient mice show only modest differences in outcomes of experimental infection ([@bib20]), despite the remarkably strong host responses to mycobacterial TLR-2 ligands when they are administered as individual stimuli. *M. tuberculosis* is a readily communicable pathogen that has infected one third of all humans, so it is unsurprising that effective immunity does not rely on a single receptor. However, in the current study, [@bib13] found that dual deletion of Myd88 and Mincle pathways reduces key aspects of the overall immune response, including TNF production. Thus, the discovery of the role of the Mincle--FcRγ--Syk pathway in TB infection now provides a tool to tease out the separate and interrelated roles of C-type lectins and TLRs as two dominant pathways in host response to mycobacteria.

Mincle opens new adjuvant avenues
=================================

Microbial products are typically screened for bioactivity at micromolar doses, but LPS, TDM, and other natural molecules are stimulatory at lower, nanomolar concentrations. Because even trace contaminates in natural products can lead to misidentification of bioactive compounds, chemical synthesis is typically necessary to validate ligands for sensitive innate receptors. The report by [@bib13] is convincing because Mincle could be activated by a synthetic analogue, trehalose dibehenate (TDB). This result also provides insight into potential molecular mechanisms of activation. Recognition of TDB by Mincle proves that activation does not require the long, branched, complex structures found in natural mycolic acids. Instead, Mincle binding appears to be specific for the ester linkage of a fatty acid to trehalose ([Fig. 2](#fig2){ref-type="fig"}). Humans express a functional Mincle orthologue ([@bib1]), so synthetic and simplified trehalose glycolipids ([@bib9]) might be developed as adjuvants for human use. Both TDM and TDB are composed of two glucose mycolate units, which are mirror images of each other ([Fig. 2](#fig2){ref-type="fig"}). Each of the glucose mycolate units is a potential Mincle epitope. Because TDM analogues that lack elements of the second unit are not strongly stimulatory, a simple, but untested model is that TDM serves as a divalent activator, which cross-links two Mincle receptors. Further testing of this model is of clinical import because it predicts that TDB-like molecules with mono- or multivalent epitopes might be developed as blockers or superagonists of Mincle. It would be tremendously satisfying to see the immunologist's dirty little secret cleaned up to exploit a potentially important pathway of macrophage and dendritic cell activation.
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